ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Randomized Phase II VELO Clinical Trial: Panitumumab + Trifluridine/Tipiracil as Anti-EGFR Rechallenge Therapy in Chemo-Refractory RAS WT mCRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Stefania Napolitano
By
ASCO GI 2023 Conference Coverage
FEATURING
Stefania Napolitano
146 views
February 16, 2023
Comments 0
Login to view comments.
Click here to Login
Videos